The present invention includes administration of a S1P receptor modulator or agonist to a mammalian patient, preferably a human, in need of treatment for multiple sclerosis, according to a dosage regimen determined on the basis of the number of blood lymphocytes of said patient , A method of treating multiple sclerosis in said mammalian patient, preferably a human.